To include your compound in the COVID-19 Resource Center, submit it here.

Genentech to manage Phase Ib/II combining Tecentriq with Seattle Genetics' SGN-LIV1A

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) will manage

Read the full 101 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE